BioCentury
ARTICLE | Finance

FDA behind; IPO in front

Trius: Regulatory pathway for antibacterial drug now clear; ready to IPO

July 19, 2010 7:00 AM UTC

Trius Therapeutics Inc. believes it has addressed the FDA issues that caused it to delay its IPO in March and hopes to price the deal next week.

The company plans to sell 6 million at $12-$14 through underwriters are Citigroup; Piper Jaffray; Canaccord; and JMP Securities. At the mid-point, Trius would raise $78 million...